查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1808879

纤维瘤市场，按药物类型、按配销通路、按国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额及预测

Desmoid Tumors Market, By Drug Type, By Distribution channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年，纤维瘤市场规模价值 29.6591 亿美元，2025 年至 2032 年的复合年增长率为 9.20%。

纤维瘤是一种罕见的非癌性（良性）肿瘤，由结缔组织细胞形成，通常位于包围肌肉、神经和血管的筋膜中。这类肿瘤具有局部侵袭性，这意味着它们可以生长并侵入附近的结构，但不会像传统癌症那样扩散到身体的其他部位。

纤维瘤市场-市场动态

全球癌症发生率上升推动纤维瘤市场成长

预计癌症发生率上升将推动未来纤维瘤市场的成长。癌症是一组以体内异常细胞失控生长和扩散为特征的疾病。这些细胞会侵入附近的组织和器官，造成伤害。全球癌症病例的增加增加了对有效和先进化疗药物的需求，这对纤维瘤市场产生了积极影响。例如，根据美国联邦政府机构国家癌症研究所的数据，到 2024 年 5 月，美国预计将诊断出 2,001,140 例新的癌症病例，预计会有 611,720 人死于癌症。 2022 年，全球新增癌症病例近 2,000 万例，死亡人数达 970 万人。到 2040 年，预计每年新增癌症病例将达到 2,990 万例，癌症相关死亡人数将达到 1,530 万例。因此，癌症发生率的上升正在推动纤维瘤市场的成长。

纤维瘤市场—关键洞察

v 根据我们的研究分析师的分析，预测期内（2025-2032 年）全球市场预计年复合成长率约为 9.20%

v 根据药物类型细分，化疗领域将成为 2025 年全球市场中最大的领域

v 根据配销通路细分，医院药房部门预计将占据全球市场的大部分份额。

v 按地区划分，北美是 2024 年的主要收入来源

纤维瘤市场-細項分析：

全球纤维瘤市场根据药物类型、配销通路和地区进行细分。

根据药物类型，市场分为五类：非类固醇抗发炎药 (NSAID)、化疗、标靶治疗、荷尔蒙治疗和其他。化疗领域在 2025 年是全球市场中最大的领域，预计在预测期内将继续主导市场。化疗虽然传统上与全身性副作用有关，但仍是重要的治疗选择，特别是对于侵袭性或无法手术的肿瘤。根据个别患者需求量身订做的合併用药方案提高了疗效和耐受性。此外，对具有更好安全性的新型化疗药物的持续研究预计将推动该领域的成长。儘管面临挑战，化疗仍是治疗方法的重要组成部分。

根据配销通路，市场分为三类：医院药房、零售药房和线上药房。预计在预测期内，医院药局将占据全球市场的绝大部分。医院药局是纤维瘤治疗的重要配销通路，因为它们可以直接接触在医疗机构接受治疗的患者。这些药房确保了基本药物的供应，并充当了医疗服务提供者和患者之间的重要纽带。它们在管理药物供应和提供咨询服务方面的作用对整个治疗过程至关重要。

纤维瘤市场—地理洞察

北美是全球纤维瘤市场最大的区域，预计在预测期内仍将保持领先地位。医疗保健支出的不断增长、技术进步的快速应用、认知度的不断提高以及北美纤维瘤患病率的不断上升，都推动了该市场的成长。 MRI 和 CT 扫描等影像技术的进步提高了检测和定位纤维瘤的能力。

预计亚太地区在预测期内的复合年增长率将位居全球市场之首。不断增长的患者群体、医疗投资和基础设施建设的增加，以及人们对罕见疾病的认知度和医疗保健可近性的提高，是推动亚太地区纤维瘤市场发展的主要因素。

纤维瘤市场-竞争格局：

纤维瘤市场竞争激烈，製药公司和研究机构都致力于开发有效的治疗方案。主要参与者包括 Horizo​​n Therapeutics Plc、Strides Pharma Science Limited、Teva Pharmaceutical Industries Ltd 和 Amneal Pharmaceuticals LLC，后者参与了标靶疗法的临床试验。专注于创新研发的小型生物技术公司和学术机构也为市场做出了贡献。竞争的驱动力在于改善治疗效果、减少副作用以及满足患者未满足的医疗需求。这既包括标靶药物和免疫疗法等新疗法的开发，也包括现有疗法的改进。监管部门的批准、临床试验结果和专利性都会影响竞争环境。

最新动态：

v 2023年8月，Horizo​​​​n Therapeutics Plc 宣布在美国推出注射用Krystexxa(R)（聚乙二醇化brentuximab vedotin），用于治疗既往接受过含蒽环类药物化疗的不可切除或复发性局部晚期或转移性软组织肉瘤（STS）成年患者。

目录

第 1 章：纤维瘤市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 纤维瘤市场（按药物类型）
    • 纤维瘤市场（按配销通路）
    • 各国家/地区纤维瘤市场摘要
    • 纤维瘤市场（按地区）
  • 竞争洞察

第三章：纤维瘤的主要市场趋势

  • 纤维瘤市场驱动因素
    • 市场驱动因素的影响分析
  • 纤维瘤市场限制
    • 市场限制的影响分析
  • 纤维瘤市场机会
  • 纤维瘤市场未来趋势

第四章：纤维瘤产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：纤维瘤市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：纤维瘤市场格局

  • 2024年纤维瘤市占率分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：纤维瘤市场－依药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 非类固醇抗发炎药（NSAIDs）
    • 化疗
    • 标靶治疗
    • 荷尔蒙疗法
    • 其他的

第 8 章：纤维瘤市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第九章：纤维瘤市场－按地区划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美纤维瘤主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（依药品类型）
    • 北美市场规模及预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲纤维瘤主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（依药品类型）
    • 欧洲市场规模及预测（按配销通路）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区纤维瘤主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依药品类型）
    • 亚太地区市场规模及预测（按配销通路）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲纤维瘤主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按药物类型）
    • 拉丁美洲市场规模及预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲的纤维瘤主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依药物类型）
    • MEA 市场规模及预测（依配销通路）
    • 沙乌地阿拉伯
    • 阿联酋
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 10 章：关键供应商分析-纤维瘤产业

  • 竞争基准化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司简介
    • Horizon Therapeutics Plc
    • Strides Pharma Science Limited
    • Teva Pharmaceutical Industries Ltd
    • Amneal Pharmaceuticals LLC
    • Hikma Pharmaceuticals PLC
    • Natco Pharma Ltd
    • Lupin, Zydus Lifesciences
    • Mylan NV
    • Assertio Holdings, Inc.
    • Mayne Pharma Group Limited
    • Alembic Pharmaceuticals Limited, Aprazer
    • Ayala Pharmaceuticals
    • SpringWorks Therapeutics, Inc
    • Iterion Therapeutics
    • Novartis AG
    • Apotex Inc.
    • Bayer AG
    • Sun Pharmaceutical Industries Ltd
    • Dr. Reddy's Laboratories Ltd
    • Endo International plc
    • Abbott
    • Getwell Pharmaceuticals
    • Others

第 11 章：360 度分析师视角

第 12 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5512

Desmoid Tumors Market size was valued at US$ 2,965.91 Million in 2024, expanding at a CAGR of 9.20% from 2025 to 2032.

Desmoid tumors are rare non-cancerous (benign) tumors that form from connective tissue cells, typically in the fascia, which surrounds muscles, nerves, and blood vessels. These tumors are locally aggressive, which means that they can grow and invade nearby structures but do not spread to other parts of the body like traditional cancer.

Desmoid Tumors Market- Market Dynamics

O Rising Global Cancer Incidence Fuels Growth In The Desmoid Tumor Market

Rising cancer rates are expected to drive future growth in the desmoid tumor market. Cancer is a group of disorders characterized by the body's abnormal cells growing and spreading out of control. These cells can infiltrate nearby tissues and organs, causing damage. The rising number of cancer cases worldwide has increased the demand for effective and advanced chemotherapeutic agents, which has a positive impact on the desmoid tumor market. For instance, in May 2024, according to the National Cancer Institute, a federal government agency based in the United States In 2024, an estimated 2,001,140 new cancer cases will be diagnosed in the United States, with 611,720 deaths expected due to the disease. In 2022, there were nearly 20 million new cancer cases and 9.7 million deaths worldwide. By 2040, the annual number of new cancer cases is expected to reach 29.9 million, with 15.3 million cancer-related deaths. As a result, rising cancer rates are driving the growth of the desmoid tumor market.

Desmoid Tumors Market- Key Insights

v As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.20% over the forecast period (2025-2032)

v Based on Drug Type segmentation, the chemotherapy segment is the largest in the global market in 2025

v Based on Distribution channel segmentation, the hospital pharmacies segment is anticipated to hold the majority of the global market.

v On the basis of region, North America was the leading revenue generator in 2024

Desmoid Tumors Market- Segmentation Analysis:

The Global Desmoid Tumors Market is segmented on the basis of Drug Type, Distribution channel, and Region.

The market is divided into five categories based on Drug Type: Non-steroidal anti-inflammatory drugs (NSAIDs), Chemotherapy, Targeted Therapy, Hormone Therapy and Others. The chemotherapy segment is the largest in the global market in 2025, and it is expected to continue to dominate the market during the forecast period. Chemotherapy, while traditionally associated with systemic side effects, remains an important treatment option, particularly for aggressive or inoperable tumors. Combination drug regimens tailored to individual patient needs have increased efficacy and tolerability. Furthermore, ongoing research into new chemotherapeutic agents with better safety profiles is expected to fuel growth in this segment. Despite its challenges, chemotherapy is still an important part of the treatment arsenal.

The market is divided into three categories based on Distribution channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment is expected to account for the majority of the global market during the forecast period. Hospital pharmacies are an important distribution channel for desmoid tumor treatments because they have direct access to patients receiving treatment in healthcare facilities. These pharmacies ensure the availability of essential medications and serve as a vital link between healthcare providers and patients. Their role in managing medication supply and offering counseling services is critical to the overall treatment process.

Desmoid Tumors Market- Geographical Insights

North America is the largest regional segment in the global desmoid tumors market, and it is expected to maintain its lead position during the forecast period. Rising healthcare expenditure, rapid adoption of technological advancements, growing awareness, and rising prevalence of desmoid tumors in North America all contribute to the market's growth. Imaging advancements, such as MRI and CT scans, have improved the ability to detect and locate desmoid tumors.

The Asia-Pacific region is expected to have the highest CAGR in the global market over the forecast period. The growing patient population, increased healthcare investments and infrastructure development, and increased awareness of rare diseases and access to healthcare are the primary drivers of the desmoid tumors market in Asia-Pacific.

Desmoid Tumors Market- Competitive Landscape:

The desmoid tumors market is competitive, with pharmaceutical companies and research institutions all working to develop effective treatment options. Key players include Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd, and Amneal Pharmaceuticals LLC, which has participated in clinical trials for targeted therapies. Smaller biotech firms and academic institutions focused on innovative research and development contribute to the market as well. Competition is driven by the need to improve treatment outcomes, reduce side effects, and meet patients' unmet medical needs. This includes both the development of new therapies, such as targeted drugs and immunotherapies, and the enhancement of existing treatments. Regulatory approvals, clinical trial results, and patentability all have an impact on the competitive environment.

Recent Developments:

v In August, 2023, Horizon Therapeutics Plc has announced the launch of Krystexxa(R) (PEGylated brentuximab vedotin) for injection in the United States for the treatment of adult patients with unresectable or recurrent locally advanced or metastatic soft tissue sarcoma (STS) who have previously received anthracycline-containing chemotherapy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DESMOID TUMORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • O Horizon Therapeutics Plc
  • O Strides Pharma Science Limited
  • O Teva Pharmaceutical Industries Ltd
  • O Amneal Pharmaceuticals LLC
  • O Hikma Pharmaceuticals PLC
  • O Natco Pharma Ltd
  • O Lupin, Zydus Lifesciences
  • O Mylan N.V.
  • O Assertio Holdings, Inc.
  • O Mayne Pharma Group Limited
  • O Alembic Pharmaceuticals Limited, Aprazer
  • O Ayala Pharmaceuticals
  • O SpringWorks Therapeutics, Inc
  • O Iterion Therapeutics
  • O Novartis AG
  • O Apotex Inc.
  • O Bayer AG
  • O Sun Pharmaceutical Industries Ltd
  • O Dr. Reddy's Laboratories Ltd
  • O Endo International plc
  • O Abbott
  • O Getwell Pharmaceuticals
  • O Others

GLOBAL DESMOID TUMORS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • O Non-steroidal anti-inflammatory drugs(NSAIDs)
  • O Chemotherapy
  • O Targeted Therapy
  • O Hormone Therapy
  • O Others

GLOBAL DESMOID TUMORS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • O Hospital Pharmacies
  • O Retail Pharmacies
  • O Online Pharmacies

GLOBAL DESMOID TUMORS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • O North America
  • U.S.
  • Canada
  • O Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • O Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • O Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • O The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Desmoid Tumors Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Desmoid Tumors Market Snippet by Drug Type
    • 2.1.2. Desmoid Tumors Market Snippet by Distribution channel
    • 2.1.3. Desmoid Tumors Market Snippet by Country
    • 2.1.4. Desmoid Tumors Market Snippet by Region
  • 2.2. Competitive Insights

3. Desmoid Tumors Key Market Trends

  • 3.1. Desmoid Tumors Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Desmoid Tumors Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Desmoid Tumors Market Opportunities
  • 3.4. Desmoid Tumors Market Future Trends

4. Desmoid Tumors Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Desmoid Tumors Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Desmoid Tumors Market Landscape

  • 6.1. Desmoid Tumors Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Desmoid Tumors Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 7.1.2. Non-steroidal anti-inflammatory drugs(NSAIDs)
    • 7.1.3. Chemotherapy
    • 7.1.4. Targeted Therapy
    • 7.1.5. Hormone Therapy
    • 7.1.6. Others

8. Desmoid Tumors Market - By Distribution channel

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Distribution channel, 2024 & 2032 (%)
    • 8.1.2. Hospital Pharmacies
    • 8.1.3. Retail Pharmacies
    • 8.1.4. Online Pharmacies

9. Desmoid Tumors Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Desmoid Tumors Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Desmoid Tumors Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.7. UK
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.7.4. UK Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.8. France
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.8.4. France Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.9. Italy
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.9.4. Italy Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.10. Spain
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.3. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.10.4. Spain Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.11. The Netherlands
      • 9.3.11.1. Overview
      • 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.3. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.11.4. The Netherlands Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Overview
      • 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.12.4. Sweden Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.13. Russia
      • 9.3.13.1. Overview
      • 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.13.4. Russia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.14. Poland
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Poland Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.15. Rest of Europe
      • 9.3.15.1. Overview
      • 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.15.4. Rest of the Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Desmoid Tumors Key Manufacturers in Asia Pacific
    • 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.4.5. APAC Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.6. China
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.6.4. China Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.7. India
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.7.4. India Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.11. Indonesia
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Indonesia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.12. Thailand
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Thailand Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.5. Latin America (LATAM)
    • 9.5.1. Overview
    • 9.5.2. Desmoid Tumors Key Manufacturers in Latin America
    • 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.5.5. LATAM Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa (MEA)
    • 9.6.1. Overview
    • 9.6.2. Desmoid Tumors Key Manufacturers in Middle East and Africa
    • 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.6.5. MEA Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.7. UAE
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. UAE Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.7.4. UAE Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Desmoid Tumors Industry

  • 10.1. Competitive Benchmarking
    • 10.1.1. Competitive Dashboard
    • 10.1.2. Competitive Positioning
  • 10.2. Company Profiles
    • 10.2.1. Horizon Therapeutics Plc
    • 10.2.2. Strides Pharma Science Limited
    • 10.2.3. Teva Pharmaceutical Industries Ltd
    • 10.2.4. Amneal Pharmaceuticals LLC
    • 10.2.5. Hikma Pharmaceuticals PLC
    • 10.2.6. Natco Pharma Ltd
    • 10.2.7. Lupin, Zydus Lifesciences
    • 10.2.8. Mylan N.V.
    • 10.2.9. Assertio Holdings, Inc.
    • 10.2.10. Mayne Pharma Group Limited
    • 10.2.11. Alembic Pharmaceuticals Limited, Aprazer
    • 10.2.12. Ayala Pharmaceuticals
    • 10.2.13. SpringWorks Therapeutics, Inc
    • 10.2.14. Iterion Therapeutics
    • 10.2.15. Novartis AG
    • 10.2.16. Apotex Inc.
    • 10.2.17. Bayer AG
    • 10.2.18. Sun Pharmaceutical Industries Ltd
    • 10.2.19. Dr. Reddy's Laboratories Ltd
    • 10.2.20. Endo International plc
    • 10.2.21. Abbott
    • 10.2.22. Getwell Pharmaceuticals
    • 10.2.23. Others

11. 360 Degree AnalystView

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us